Robert Satriale, MD
Pulmonary Disease · Philadelphia, PANPI 1154321719
Payments from drug & device makers
Across 337 payments — averaging $21.27 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AstraZeneca$1K
- GSK$773
- Actelion Pharmaceuticals US, Inc.$507
- Insmed, Inc.$460
- Boehringer Ingelheim$456
- Johnson & Johnson$427
- plus $3K from 30 others
What the payments were for
- Food & beverage$6,94897%
- Education$2213%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AstraZeneca(2 entities) | 68 | $1,339 |
| GSK | 46 | $773 |
| Actelion Pharmaceuticals US, Inc. | 18 | $507 |
| Insmed, Inc. | 16 | $460 |
| Boehringer Ingelheim | 24 | $456 |
| Johnson & Johnson | 16 | $427 |
| Harmony Biosciences LLC | 16 | $368 |
| Jazz Pharmaceuticals Inc. | 16 | $329 |
| Mylan Specialty L.p. | 14 | $279 |
| Genentech USA, Inc. | 13 | $222 |
| Inspire Medical Systems, Inc. | 4 | $216 |
| Takeda Pharmaceuticals U.S.A., Inc. | 8 | $209 |
| Grifols USA, LLC | 8 | $165 |
| Viatris Specialty LLC | 5 | $145 |
| United Therapeutics Corporation | 7 | $135 |
| Merck | 8 | $135 |
| Regeneron Healthcare Solutions, Inc. | 7 | $133 |
| Sanofi | 6 | $125 |
| Mallinckrodt Enterprises LLC | 4 | $119 |
| Advanced Respiratory, Inc | 5 | $102 |
| Philips North America LLC | 6 | $95 |
| Pfizer | 3 | $55 |
| CSL Behring | 2 | $50 |
| Resmed Corp | 2 | $41 |
| Shire North American Group Inc | 2 | $39 |
| Biomerieux Inc | 1 | $30 |
| Circassia Inc. | 2 | $29 |
| Eisai Inc. | 2 | $28 |
| Mallinckrodt Hospital Products Inc. | 1 | $27 |
| Pulmonx Corporation | 1 | $24 |
| Tactile Systems Technology Inc | 1 | $22 |
| Vifor Pharma, Inc. | 1 | $20 |
| Paratek Pharmaceuticals, Inc. | 1 | $18 |
| Avadel CNS Pharmaceuticals, LLC | 1 | $18 |
| Nabriva Therapeutics, PLC | 1 | $17 |
| Amgen | 1 | $13 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- Inspire$156
How this compares
$7,169 in reported general payments places this provider in the 70th percentile of 703 pulmonary disease providers in Pennsylvania.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| OfevNintedanib Esylate | 97 | $1,278,260 |
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 268 | $195,854 |
| Dupixent PenDupilumab | 42 | $162,180 |
| ZemairaAlpha-1-Proteinase Inhibitor | 14 | $144,548 |
| XolairOmalizumab | 14 | $106,859 |
| NucalaMepolizumab | 24 | $86,808 |
| Anoro ElliptaUmeclidinium Brm/Vilanterol Tr | 155 | $83,729 |
| Breztri AerosphereBudesonide/Glycopyr/Formoterol | 84 | $59,748 |
| Ambrisentan | 13 | $36,823 |
| Stiolto RespimatTiotropium Br/Olodaterol Hcl | 61 | $33,897 |
| Tadalafil | 25 | $29,880 |
| Breo ElliptaFluticasone/Vilanterol | 52 | $28,794 |
| Advair HfaFluticasone Propion/Salmeterol | 49 | $26,216 |
| Incruse ElliptaUmeclidinium Bromide | 45 | $25,548 |
| Pirfenidone | 29 | $22,546 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Boehringer IngelheimOfev, Stiolto Respimat, Spiriva Respimat | $456 | $1,324,442180 claims |
| GSKTrelegy Ellipta, Nucala, Anoro Ellipta, Breo Ellipta, Incruse Ellipta | $773 | $431,344572 claims |
| CSL BehringZemaira | $50 | $144,54814 claims |
| AstraZenecaBreztri Aerosphere, Symbicort, Bevespi Aerosphere | $1,339 | $87,139167 claims |
| Johnson & JohnsonXarelto | $427 | $12,88616 claims |
| MerckDulera | $135 | $6,23417 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 70th percentile of 703 pulmonary disease providers in Pennsylvania.
Other pulmonary disease in Philadelphia
- Gerard CrinerPhiladelphia$18.2M
- David WheelerPhiladelphia$7.7M
- Steven AlbeldaPhiladelphia$5.5M
- Steven KelsenPhiladelphia$847K
- Parth RaliPhiladelphia$814K
- Kartik ShenoyPhiladelphia$701K
- Christopher ManleyPhiladelphia$580K
- Michaela AndersonPhiladelphia$515K
- Michael BaramPhiladelphia$501K
- Ross SummerPhiladelphia$483K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.